The Expression Changes and Clinical Significance of Serum miRNA-1 in Patients with Heart Failure

Abstract

To investigate the expression changes and clinical significance of micro ribonucleic acid-1 in patients with heart failure. Ninety-four heart failure patients admitted to our hospital from December 2018 to December 2019 were selected as the study group and another 94 healthy check-ups in the same period were selected as the control group. The differences of micro ribonucleic acid-1 expression in the two study groups and its relationship with clinical indicators were compared and analyzed. The results showed that the plasma micro ribonucleic acid-1 expression level in the study group was higher and lower than that in the control group and the monocyte micro ribonucleic acid-1 expression level in the study group was lower than that in the control group and the difference was statistically significant (p<0.05). The plasma and monocyte micro ribonucleic acid-1 expression levels decreased significantly with the increase of heart function grade in heart failure and the difference was statistically significant (p<0.05). There was no statistically significant difference in plasma micro ribonucleic acid-1 expression levels among patients with different etiologies of heart failure (p>0.05). Micro ribonucleic acid-1 expression levels were positively correlated with brain natriuretic peptide and left ventricular end diastolic diameter and negatively correlated with left ventricular ejection fraction (p<0.05). Micro ribonucleic acid-1, left ventricular ejection fraction and left ventricular end diastolic diameter were independent risk factors for heart failure, with statistically significant differences (p<0.05). The expression level of micro ribonucleic acid-1 in heart failure patients is reduced and the expression is more obvious with the increase of the disease, which is expected to be used as a marker for the diagnosis and judgment of heart failure.